Dr. Mark Kay and colleagues have created antibiotic-selectable, non-silencing plasmid vectors that can be prepared by conventional methods and provide persistent high levels of transgene expression.
Researchers in Dr. Mark Kay's laboratory at Stanford University have designed a new liver-specific expression cassette for inserting genes into double-stranded AAV (adeno-associated virus) vectors for gene therapy.